Adaptive Biotech says clonoSEQ MRD test features in 33 ASCO, EHA presentations

Adaptive Biotechnologies

Adaptive Biotechnologies

ADPT

0.00
  • Adaptive Biotechnologies flagged clonoSEQ MRD test data across 33 presentations scheduled for ASCO May 29–June 3, 2026, and EHA June 11–14, 2026.
  • Presentations are set to position clonoSEQ as a decision-support tool for response assessment, ongoing monitoring, and MRD-guided treatment choices in blood cancers.
  • Updates include follow-on results from multiple myeloma trials, including a final CEPHEUS analysis tied to an FDA decision that relied on an MRD endpoint.
  • CLL studies are expected to show MRD-guided therapy stopping strategies can support durable time off treatment in selected patients.
  • ALL findings are slated to indicate clonoSEQ can detect residual disease more reliably than flow cytometry, improving outcome prediction.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Adaptive Biotechnologies Corporation published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605290730PRIMZONEFULLFEED9728696) on May 29, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.